BioNTech
BNTX
293 hedge funds and large institutions have $4.96B invested in BioNTech in 2022 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 83 increasing their positions, 95 reducing their positions, and 38 closing their positions.
21% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 38
2% more funds holding
Funds holding: 287 → 293 (+6)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0.48% less ownership
Funds ownership: 14.26% → 13.78% (-0.48%)
13% less repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 95
16% less capital invested
Capital invested by funds: $5.9B → $4.96B (-$938M)
42% less call options, than puts
Call options by funds: $394M | Put options by funds: $677M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Flossbach Von Storch
Cologne,
Germany
|
+$175M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$79.2M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$49.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$49.1M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$26.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PG
Pendal Group
Sydney,
Australia
|
-$334M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$127M |
| 3 |
D.E. Shaw & Co
New York
|
-$39.6M |
| 4 |
Jennison Associates
New York
|
-$31.7M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.1M |
BNTX Hedge Fund Activity: Q2 2022 in Review
293 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q2 2022, worth a combined $4.96B — down 16% from $5.9B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new BNTX positions and 38 closed out — a net gain of 8 holders — while 83 added to existing stakes and 95 trimmed.
The largest buyer was Flossbach Von Storch, adding an estimated $175M. The largest seller was Pendal Group, exiting entirely with an estimated $334M sold.
- 293 institutional investors held BioNTech (BNTX) as of Q2 2022, up from 287 in Q1 2022.
- Funds reported $4.96B of BioNTech stock for Q2 2022, down 16% quarter-over-quarter.
- 46 funds opened new BioNTech positions in Q2 2022 and 38 closed out, a net change of +8 holders.
- The largest BioNTech buyer in Q2 2022 was Flossbach Von Storch, an estimated $175M added.
- The largest BioNTech seller in Q2 2022 was Pendal Group, an estimated $334M sold.
Based on aggregated 13F filings for Q2 2022.